Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the 2022 Annual Meeting of Stockholders held by Jaguar Health, Inc. on June 10, 2022. The filing details the voting results for four proposals submitted to shareholders.
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. No financial statements are included in this document.
Material Changes and Voting Results
Four proposals were submitted and approved by the stockholders. The specific voting outcomes were:
- Proposal 1 (Election of Directors): Three Class I directors were elected for a three-year term.
- James J. Bochnowski: 23,086,410 For; 2,164,475 Withheld.
- Lisa A. Conte: 23,202,917 For; 2,041,534 Withheld.
- Jonathan B. Siegel: 23,266,887 For; 1,982,465 Withheld.
- Proposal 2 (Ratification of Auditors): Ratified the appointment of RBSM LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- Votes: 35,370,077 For; 1,937,554 Against; 163,328 Abstained.
- Proposal 3 (Issuance of Shares): Approved the issuance of voting common stock upon the exchange of certain royalty interests and a promissory note previously issued to accredited investors (pursuant to Nasdaq Rule 5635(d)).
- Votes: 20,936,276 For; 2,779,713 Against; 402,073 Abstained.
- Proposal 4 (Adjournment Authority): Granted discretionary authority to adjourn the meeting to solicit additional proxies if necessary to approve Proposal 3.
- Votes: 22,250,242 For; 2,595,707 Against; 415,768 Abstained.
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, or specific risk factors. It references a press release (Exhibit 99.1) regarding the meeting results, which is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the terms of the royalty interests and promissory note referenced in Proposal 3 to understand the potential dilution impact.
- Review the Company's Proxy Statement for detailed biographies of the newly elected directors and the rationale for the auditor ratification.
- Check subsequent filings (e.g., 10-Q or 10-K) for the actual financial performance and liquidity status, as this 8-K contains no financial data.
- Confirm the final issuance of shares related to Proposal 3 in future transaction reports.